Novocell Becomes ViaCyte, Inc, as it Accelerates Pre-clinical Development of a Stem Cell Derived Treatment for Diabetes

On May 5, 2010 Novocell, Inc., a preclinical stage stem cell engineering company focused on diabetes, reported the Company’s shareholders and Board of Directors approved a name change to ViaCyte, Inc (Press release, ViaCyte, MAY 5, 2010, View Source [SID1234517100]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The name ViaCyte retains the Company’s identity as a leading cell therapy company, as"-cyte" is derived from the Greek "kytos" which means cell. As the Company is moving towards the market, clear and unambiguous brand recognition is increasingly important. With its new name, the Company has also adopted a new corporate logo. An abstract flower emphasizes the rejuvenation possible through a stem cell-derived therapy.

The name ViaCyte was previously used by ViaCell, Inc., but their use was discontinued following acquisition of ViaCell by Perkin Elmer, Inc. The Company has acquired all rights to the ViaCyte service marks and internet domain name addresses previously owned by ViaCell. The Company’s product developments are not related to those of ViaCell or Perkin Elmer.

The Company’s new name also provides consolidation. The Company is the result of a three-way merger in 2004 of Novocell, Inc. (Irvine, CA), Cythera, Inc. (San Diego, CA) and BresaGen, Inc. (Athens, GA). Going forward, the Company is focused on stem cell innovations initiated in its San Diego and Athens locations, and has discontinued work on PEG-encapsulated islets that were the focus of its former Irvine location. All of the Company’s operations will use the ViaCyte name. The Company’s wholly owned subsidiary in Athens, Georgia will take the name ViaCyte Georgia.